BNY Trust seeks $26.5M capital reduction

Summary#

BNY Trust Company of Canada plans to ask the Superintendent of Financial Institutions (Canada) for permission to reduce the stated capital of its common shares by up to $26.5 million. A special resolution by the company’s sole shareholder was passed on September 12, 2024, and the company gave notice of the plan on September 21, 2024.

What it does#

• Reduces the stated capital account for the company’s common shares by up to $26.5 million.
• The money from that reduction would be distributed to the company’s sole shareholder.
• The company’s Chief Financial Officer will decide how much of the $26.5 million limit to actually reduce, if approval is granted.
• The change needs approval under the Trust and Loan Companies Act (Canada) from the Superintendent of Financial Institutions (Canada) before it can happen.
• The published notice is only an announcement; it does not mean approval has been given.

Who's affected#

• The immediate recipient is the company’s sole shareholder (unnamed in the notice).
• BNY Trust Company of Canada itself is affected because the company’s capital accounts and balance sheet would change.
• Creditors, clients, or depositors could be indirectly affected if the reduction meaningfully changes the company’s financial buffer — but any effect depends on whether the regulator approves the reduction and on the company’s overall financial position.
• It is unclear from the notice whether any other parties (for example, named investors or clients) will be directly affected.

Why it matters#

• Reducing stated capital means the company would move up to $26.5 million out of its capital account and give it to its shareholder. That can change how much financial cushion the company has to absorb losses.
• Regulators review these requests to make sure public and creditor protections are maintained before allowing capital reductions.
• For most members of the public this is a routine corporate finance step with limited immediate impact, but it is important for people tracking the company’s financial strength or regulatory approvals.